Essential Premium

CTA Performance Splinters As a Late Surge Lifts Some, But Not All

Indexes posted steady monthly gains into year end, but individual managers diverged sharply — from double digit returns to double digit losses.tau

From Deep Losses to Remarkable Gains: Biopharma’s Wildest Year in Recent Memory

A spring pivot in sentiment turned one of the sector’s toughest stretches into a breakout year for the specialist funds.

Sponsored

Portfolio Finance: 101

Valiant Topped the Tiger Crowd in 2025

Most Tiger Cubs and Grandcubs posted strong results in either their long-short or long-only funds.

Related Content

RTW and Rivals Cash In as Biopharma Roars Back

Stephen Taub

Caxton Posts Its Best Year Since Andrew Law Took Control

Stephen Taub

Behind Bridgewater’s Surge

Stephen Taub

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram